Jeffrey L. C. Ives
Independent DirectorDr. Jeffrey L. C. Ives, Ph.D. also known as Jeff, serves as Chairman of the Board at Pinteon Therapeutics, Inc. He is an Advisor to Access Biotechnology and a Principal at NeuroPharma Advisors, LLC. Dr. Ives served as a Venture Partner till April 2021 at New Leaf Venture Partners, LLC where he focused on the biopharmaceutical arena since January 2017. Prior to New Leaf, Dr. Ives was a Principal for NeuroPharma Advisors, LLC. He serves as Member of Development Advisory Board at Embera NeuroTherapeutics Inc. He served as the Chief Executive Officer of Satori Pharmaceuticals Incorporated from January 08, 2009 to 2013. Dr. Ives served as an Executive-In-Residence at PureTech Health plc. He has senior scientific leadership experience in the development of novel therapeutics, with an emphasis on drugs for central nervous system diseases. He served as Senior Vice President and Head Pfizer portfolio leader at Pfizer, where he led the optimization of the entire global research candidate portfolio. Dr. Ives led the CNS, pain and oncology research teams at Pfizer for over two decades. He served as Senior Vice President of the Pharmacokinetics, Dynamics & Metabolism organization at Pfizer from 2001 to 2007 and served as its Vice President of Central Nervous System Research and Executive Director of Central Nervous System Medicinal Chemistry. He also serves on the boards of several neurodegenerative disease companies including Pinteon Therapeutics and Orthogonal Neuroscience. He has led CNS and oncology teams that have discovered greater than 50 clinical candidates including multiple new products such as Geodon, Chantix and Tarceva and was a co-leader of in-licensing teams for Prizer products including Celebrex, Bextra and Aricept. He has been an Independent Director of Acumen Pharmaceuticals, Inc since May 2014. He served as a Director of Satori Pharmaceuticals Incorporated. He has been a Director at Astrocyte Pharmaceuticals Inc. since December 2014. He has been an Independent Director at Cara Therapeutics, Inc., since July 16, 2014. Dr. Ives holds Ph.D. in Chemistry and master degrees from Yale University and received his bachelor of arts Degree in Chemistry from Colgate University.
Positions
- Company NameAcumen Pharmaceuticals, Inc.Stock CodeABOSPositionIndependent DirectorColleagues
- DJDaniel J. O'ConnellCEO & Director
- GSGeorge S. GolumbeskiIndependent Chairman of the Board
- JDJames DohertyPresident & Chief Development Officer
- MZMatt ZugaCFO & Chief Business Officer
- GAGrant A. KrafftCo-Founder
- CECaleb E. FinchCo-Founder
- LSLaura StoppelIndependent Director
- KCKimberlee Cobleigh DrapkinIndependent Director
